tiprankstipranks
Merck & Company (CH:6MK)
NYSE:6MK
Switzerland Market
6MK
Merck & Company
RESEARCH TOOLSreports

Merck & Company (6MK) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

6MK Analyst Ratings

Moderate Buy
19Ratings
Moderate Buy
13 Buy
6 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Merck
& Company
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6MK Stock 12 Month Forecast

Average Price Target

CHF109.10
▲(12.96% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is CHF109.10 with a high forecast of CHF143.07 and a low forecast of CHF89.52. The average price target represents a 12.96% change from the last price of CHF96.58.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"CHF88","102":"CHF102","116":"CHF116","130":"CHF130","144":"CHF144"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":143.06940697,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF143.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":109.100413695,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF109.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89.51828816,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF89.52</span>\n  </div></div>","useHTML":true}}],"tickPositions":[88,102,116,130,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.578,100.15426207461539,103.73052414923077,107.30678622384616,110.88304829846153,114.45931037307692,118.0355724476923,121.61183452230769,125.18809659692307,128.76435867153845,132.34062074615383,135.91688282076922,139.4931448953846,{"y":143.06940697,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.578,97.54126259192309,98.50452518384616,99.46778777576924,100.43105036769231,101.39431295961539,102.35757555153846,103.32083814346154,104.28410073538461,105.2473633273077,106.21062591923076,107.17388851115385,108.13715110307692,{"y":109.100413695,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.578,96.03494524307692,95.49189048615385,94.94883572923077,94.4057809723077,93.86272621538461,93.31967145846154,92.77661670153846,92.23356194461539,91.6905071876923,91.14745243076923,90.60439767384615,90.06134291692308,{"y":89.51828816,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":96.578,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.578,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF143.07Average Price TargetCHF109.10Lowest Price TargetCHF89.52
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on CH:6MK
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG), Zevra Therapeutics (NASDAQ: ZVRA) and Merck & Company (NYSE: MRK)
Wells Fargo Analyst forecast on CH:6MK
Mohit Bansal
Wells Fargo
Wells Fargo
CHF142.27→CHF115.89
Buy
20.00%
Upside
Reiterated
06/08/26
Wells Fargo Keeps Their Buy Rating on Merck & Company (MRK)
Bank of America Securities Analyst forecast on CH:6MK
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF103.91
Buy
7.58%
Upside
Reiterated
06/02/26
Merck’s Lung Cancer Strategy and Next-Gen PD-1/VEGF Pipeline Underpin Buy Rating, $130 Price Target Reiterated
Guggenheim Analyst forecast on CH:6MK
Vamil Divan
Guggenheim
Guggenheim
CHF111.9
Buy
15.86%
Upside
Reiterated
06/02/26
Merck & Company (MRK) Receives a Buy from Guggenheim
Citi Analyst forecast on CH:6MK
Geoff Meacham
Citi
Citi
CHF99.91
Hold
3.45%
Upside
Reiterated
06/02/26
Hold Rating Reiterated on Merck as sac-TMT Phase 3 Win Offsets Full Valuation; $125 Price Target Unchanged
Goldman Sachs Analyst forecast on CH:6MK
Asad Haider
Goldman Sachs
Goldman Sachs
CHF106.3→CHF109.5
Buy
13.38%
Upside
Reiterated
06/02/26
Goldman Sachs Reaffirms Their Buy Rating on Merck & Company (MRK)
Scotiabank Analyst forecast on CH:6MK
Louise Chen
Scotiabank
Scotiabank
CHF108.7
Buy
12.55%
Upside
Reiterated
06/02/26
Scotiabank Sticks to Their Buy Rating for Merck & Company (MRK)
UBS Analyst forecast on CH:6MK
Michael Yee
UBS
UBS
CHF115.89
Buy
20.00%
Upside
Reiterated
06/02/26
Merck & Company (MRK) Receives a Buy from UBS
Barclays Analyst forecast on CH:6MK
Emily Field
Barclays
Barclays
CHF111.9
Buy
15.86%
Upside
Reiterated
06/01/26
Barclays Reaffirms Their Buy Rating on Merck & Company (MRK)
RBC Capital Analyst forecast on CH:6MK
Trung Huynh
RBC Capital
RBC Capital
―
Buy
―
Reiterated
05/21/26
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Merck & Company (MRK)
Jefferies Analyst forecast on CH:6MK
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF110.3
Buy
14.21%
Upside
Reiterated
05/19/26
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
Argus Research Analyst forecast on CH:6MK
Jasper Hellweg
Argus Research
Argus Research
CHF103.91
Buy
7.58%
Upside
Reiterated
05/08/26
Argus Research Remains a Buy on Merck & Company (MRK)
Erste Group Analyst forecast on CH:6MK
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Merck & Company (NYSE: MRK)
BMO Capital Analyst forecast on CH:6MK
Evan Seigerman
BMO Capital
BMO Capital
CHF107.9
Buy
11.72%
Upside
Reiterated
05/04/26
BMO Capital Remains a Buy on Merck & Company (MRK)
Morgan Stanley Analyst forecast on CH:6MK
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF87.12→CHF89.52
Hold
-7.31%
Downside
Reiterated
05/01/26
Morgan Stanley Sticks to Its Hold Rating for Merck & Company (MRK)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on CH:6MK
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: 10x Genomics (NASDAQ: TXG), Zevra Therapeutics (NASDAQ: ZVRA) and Merck & Company (NYSE: MRK)
Wells Fargo Analyst forecast on CH:6MK
Mohit Bansal
Wells Fargo
Wells Fargo
CHF142.27→CHF115.89
Buy
20.00%
Upside
Reiterated
06/08/26
Wells Fargo Keeps Their Buy Rating on Merck & Company (MRK)
Bank of America Securities Analyst forecast on CH:6MK
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF103.91
Buy
7.58%
Upside
Reiterated
06/02/26
Merck’s Lung Cancer Strategy and Next-Gen PD-1/VEGF Pipeline Underpin Buy Rating, $130 Price Target Reiterated
Guggenheim Analyst forecast on CH:6MK
Vamil Divan
Guggenheim
Guggenheim
CHF111.9
Buy
15.86%
Upside
Reiterated
06/02/26
Merck & Company (MRK) Receives a Buy from Guggenheim
Citi Analyst forecast on CH:6MK
Geoff Meacham
Citi
Citi
CHF99.91
Hold
3.45%
Upside
Reiterated
06/02/26
Hold Rating Reiterated on Merck as sac-TMT Phase 3 Win Offsets Full Valuation; $125 Price Target Unchanged
Goldman Sachs Analyst forecast on CH:6MK
Asad Haider
Goldman Sachs
Goldman Sachs
CHF106.3→CHF109.5
Buy
13.38%
Upside
Reiterated
06/02/26
Goldman Sachs Reaffirms Their Buy Rating on Merck & Company (MRK)
Scotiabank Analyst forecast on CH:6MK
Louise Chen
Scotiabank
Scotiabank
CHF108.7
Buy
12.55%
Upside
Reiterated
06/02/26
Scotiabank Sticks to Their Buy Rating for Merck & Company (MRK)
UBS Analyst forecast on CH:6MK
Michael Yee
UBS
UBS
CHF115.89
Buy
20.00%
Upside
Reiterated
06/02/26
Merck & Company (MRK) Receives a Buy from UBS
Barclays Analyst forecast on CH:6MK
Emily Field
Barclays
Barclays
CHF111.9
Buy
15.86%
Upside
Reiterated
06/01/26
Barclays Reaffirms Their Buy Rating on Merck & Company (MRK)
RBC Capital Analyst forecast on CH:6MK
Trung Huynh
RBC Capital
RBC Capital
―
Buy
―
Reiterated
05/21/26
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Merck & Company (MRK)
Jefferies Analyst forecast on CH:6MK
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF110.3
Buy
14.21%
Upside
Reiterated
05/19/26
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
Argus Research Analyst forecast on CH:6MK
Jasper Hellweg
Argus Research
Argus Research
CHF103.91
Buy
7.58%
Upside
Reiterated
05/08/26
Argus Research Remains a Buy on Merck & Company (MRK)
Erste Group Analyst forecast on CH:6MK
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Merck & Company (NYSE: MRK)
BMO Capital Analyst forecast on CH:6MK
Evan Seigerman
BMO Capital
BMO Capital
CHF107.9
Buy
11.72%
Upside
Reiterated
05/04/26
BMO Capital Remains a Buy on Merck & Company (MRK)
Morgan Stanley Analyst forecast on CH:6MK
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF87.12→CHF89.52
Hold
-7.31%
Downside
Reiterated
05/01/26
Morgan Stanley Sticks to Its Hold Rating for Merck & Company (MRK)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

3 Months
Asad HaiderGoldman Sachs
Success Rate
10/11 ratings generated profit
91%
Average Return
+6.77%
Copying Asad Haider's trades and holding each position for 3 Months would result in 90.91% of your transactions generating a profit, with an average return of +6.77% per trade.
1 Year
Asad HaiderGoldman Sachs
Success Rate
11/11 ratings generated profit
100%
Average Return
+23.64%
Copying Asad Haider's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +23.64% per trade.
2 Years
Asad HaiderGoldman Sachs
Success Rate
11/11 ratings generated profit
100%
Average Return
+23.81%
Copying Asad Haider's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +23.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6MK Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
1
1
1
Buy
32
40
44
49
38
Hold
18
22
20
18
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
50
62
65
68
53
In the current month, 6MK has received 39 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. 6MK average Analyst price target in the past 3 months is 109.10.
Each month's total comprises the sum of three months' worth of ratings.

6MK Financial Forecast

6MK Earnings Forecast

Next quarter’s earnings estimate for 6MK is CHF1.68 with a range of CHF1.59 to CHF1.83. The previous quarter’s EPS was -CHF1.02. 6MK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.
Next quarter’s earnings estimate for 6MK is CHF1.68 with a range of CHF1.59 to CHF1.83. The previous quarter’s EPS was -CHF1.02. 6MK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.

6MK Sales Forecast

Next quarter’s sales forecast for 6MK is CHF13.06B with a range of CHF12.65B to CHF13.77B. The previous quarter’s sales results were CHF12.93B. 6MK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.
Next quarter’s sales forecast for 6MK is CHF13.06B with a range of CHF12.65B to CHF13.77B. The previous quarter’s sales results were CHF12.93B. 6MK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.

6MK Stock Forecast FAQ

What is CH:6MK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is 109.10.
    What is CH:6MK’s upside potential, based on the analysts’ average price target?
    Merck & Company has 12.96% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Merck & Company a Buy, Sell or Hold?
          Merck & Company has a consensus rating of Moderate Buy, which is based on 13 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Merck & Company’s share price target?
            The average share price target for Merck & Company is 109.10. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF143.07 ,and the lowest forecast is CHF89.52. The average share price target represents 12.96% Increase from the current price of CHF96.58.
              What do analysts say about Merck & Company?
              Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of Merck & Company?
                To buy shares of CH:6MK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.